Bupropion Dosing for Major Depressive Disorder
For major depressive disorder, start bupropion extended-release (XL) at 150 mg once daily in the morning, then increase to the target dose of 300 mg once daily after 4 days if tolerated, with a maximum dose of 300 mg daily. 1
Initial Dosing and Titration
The FDA-approved dosing schedule for bupropion XL in depression is straightforward:
- Starting dose: 150 mg once daily in the morning
- Titration: After 4 days, increase to 300 mg once daily in the morning
- Maximum dose: 300 mg daily (do not exceed this dose) 1
The extended-release formulation should be swallowed whole—never crushed, divided, or chewed—and can be taken with or without food 1. The morning administration is critical to minimize insomnia risk.
Alternative Formulations
For the sustained-release (SR) formulation used in smoking cessation contexts, the dosing differs:
- Days 1-3: 150 mg once daily in the morning
- Day 4 onward: 150 mg twice daily if tolerated
- Maximum: 300 mg per day total 2, 3
Clinical trials have demonstrated that 150 mg once daily may be as effective as 150 mg twice daily for depression, offering improved convenience and tolerability 4.
Duration of Treatment
Acute episodes of depression require several months or longer of antidepressant treatment beyond the initial response. 1 Periodically reassess the need for maintenance treatment and appropriate dosing. When discontinuing treatment at 300 mg daily, taper to 150 mg once daily before complete discontinuation 1.
Special Population Adjustments
Hepatic Impairment
- Moderate to severe (Child-Pugh 7-15): Maximum 150 mg every other day
- Mild (Child-Pugh 5-6): Consider reducing dose and/or frequency 1
Renal Impairment
Consider reducing dose and/or frequency in patients with GFR <90 mL/min, as bupropion and metabolites are renally cleared and may accumulate 1
Elderly Patients
Full adult doses can be given, but monitor closely as elderly patients are more likely to have decreased renal function 1
Critical Safety Considerations
Absolute contraindications:
- Seizure disorders or conditions increasing seizure risk (stroke, brain metastases, eating disorders)
- Current or recent (within 14 days) MAOI use
- Concurrent tamoxifen use
- Closed-angle glaucoma 3
The seizure risk at therapeutic doses (≤300 mg/day) is approximately 0.1%, which is within the range of other antidepressants 5. However, this risk increases substantially with:
- Doses exceeding 300 mg daily
- Rapid dose escalation
- Predisposing factors (head trauma, CNS tumor, abrupt alcohol/benzodiazepine withdrawal)
Clinical Pearls
Monitor for neuropsychiatric effects, particularly in patients under 24 years old, though recent large trials showed no increased risk compared to placebo 3. Bupropion's activating properties mean it can worsen agitation in some patients but may improve apathy and energy in others 6.
For patients with comorbid anxiety and depression, bupropion can be effective, though SSRIs may be preferred for severe anxious depression 7, 8. Starting at lower doses and monitoring for anxiogenic symptoms is prudent 8.
Weight considerations: Unlike many antidepressants, bupropion is associated with modest weight loss (0.5-1.0 kg) rather than weight gain 4. At 300 mg daily, bupropion has demonstrated efficacy for long-term treatment of recurrent major depression 9.
Drug interactions: Allow at least 14 days between discontinuing an MAOI and starting bupropion, and vice versa 1. Exercise caution with other medications that lower seizure threshold or are metabolized via CYP2D6.